Vedolizumab treatment persistence and safety in a 2‐year data analysis of an extended access programme

por Danese, Silvio, Subramaniam, Kavitha, Van Zyl, Jan, Adsul, Shashi, Lindner, Dirk, Roth, Jeannine, Vermeire, Séverine
Publicado 2020

Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn’s Disease or Ulcerative Colitis

por Vermeire, Séverine, Lukáš, Milan, Magro, Fernando, Adsul, Shashi, Lindner, Dirk, Rosario, Maria, Roth, Jeannine, Danese, Silvio
Publicado 2020